ABSTRACT The efficacy of ketotifen, a tricyclic benzocycloheptathiophene derivative, was assessed in an outpatient clinical trial and in a group of 12 asthmatic subjects with exerciseinduced asthma. Subjects in the outpatient trial had mild asthma and consisted of two groups: a group of 24 atopic asthmatics with at least one positive skin test reaction and with an associated history of bronchial reactivity to at least one allergen; and a group of eight asthmatics with one or more positive skin prick tests but no bronchial reactivity to an allergen. Both groups took four weeks medication of ketotifen 1 mg bd and placebo in a randomised double-blind crossover study. There was no difference between ketotifen and placebo for any measurement made during the study and consequently no evidence of drug efficacy. The exercise study followed a standardised protocol and each subject took in random double-blind order, placebo, 1 mg, 2 mg, and 4 mg ketotifen two hours before exercise. There was no difference in the mean decreases in lung function from pre-exercise baseline values after three doses of ketotifen than with placebo. Drug levels suggested ketotifen was well absorbed. It would appear that if given for a period of only four weeks ketotifen has no beneficial effects in the management of mild asthma, and that a single dose before exercise does not modify exercise-induced asthma.
Ketotifen, an orally active tricyclic benzocycloheptathiophene derivative, has several properties suggesting it might be useful in the management of asthma.' 2 It inhibits passive cutaneous anaphylaxis and has a mast cell stabilising effect. It is also a potent antihistamine specific for Hi receptors with little anticholinergic activity and it raises intracellular cyclic-AMP levels by inhibiting phosphodiesterase. ' 2 Ketotifen has been shown to be effective in preventing histamine-induced bronchospasm,34 aspirin and tartrazine-induced asthma,5 and as effective as disodium cromoglycate in controlling allergen-induced bronchospasm.3 Proof of its efficacy in preventing exercise-induced bronchospasm is confined to a single comparative study with cromoglycate which showed good protection in eight of 11 and forced expired volume in one second (FEV1) but these measurements were at least 70% of predicted normal at the time of entry to the study. All subjects had at least one skin prick test reaction greater than 3 mm to a battery of common allergens. All were taking regular medication, either disodium cromoglycate or bronchodilator aerosol, or both. One patient took inhaled beclomethasone but no one was taking oral corticosteroids. Bronchodilator treatment continued as necessary. There were two treatment periods each of four weeks. The first period was preceded by a "run in" week in which cromoglycate was stopped, lung function was assessed, and diary cards started. At the start of the second week ketotifen 1 mg capsules or placebo capsules twice daily were started. After four weeks of the first treatment period a week was allowed for "washout" of any possible beneficial effect then the alternative preparation was taken for a further four weeks. The subjects were assessed at the start of the study, at the end of the fifth week, and at the end of the tenth week. Each patient recorded morning and evening PEFR before bronchodilator, daily severity of asthma (scored from 0-10), total daily number of bronchodilator "puffs" needed, and whether other drugs were consumed. All side-effects were noted. At the end of the study each patient was asked to score each trial period thus: 1=very good, 2=good, 3=fair, 4 =useless. Each patient was questioned about side-effects at the end of each treatment period.
EXERCISE STUDY
Twelve volunteers who had previously been shown to have a fall of PEFR or FEV1 greater than 20% after exercise were tested on four separate occasions. They were exercised on a treadmill according to a standard protocol similar to that of Eggleston and Guerrant,9 so that heart rate reached 80% of maximum predicted during the last two minutes of the six-minute period of exercise. Bronchodilators or disodium cromoglycate were not taken for at least 12 hours before each study. Baseline lung function had to be within 10% of the values on the first study day on each subsequent study day. A single dose of ketotifen 1 mg, 2 mg, 4 mg, or placebo were taken in random order two hours before exercise. Peak expiratory flow rate, FEV1, FVC, and expiratory flow at mid vital capacity (V50) were recorded 15 and one minute before exercise and at 0, 3, 5, 10, 15, and 20 minutes after. The spirometer for measuring expired volumes and V50 was a dry wedge spirometer ("Floop" Oldelft, England Ltd). Venous blood for estimation of drug levels was drawn two hours (immediately before exercise) and three hours after ingestion. Plasma ketotifen concentrations were measured by radioimmunoassay.
Both studies were approved by the hospital ethics committee and the patients gave informed verbal consent for the outpatient study and written consent for the exercise protocol.
The data obtained from each study were analysed as group mean values by Student's paired t test.
Results

OUTPATIENT STUDY
Thirty-two subjects entered the study but one dropped out at the start of the second trial period because of side-effects. The remainder were divided into two groups according to whether they gave a history of bronchial reactivity to at least one common allergen (group 1) or not (group 2). All subjects were skin test positive to the more common allergens-house dust mite, grasses, and various shrubs or flowers. Subjects allocated to group 1 either had a long standing history of bronchial reactivity to one or more of these allergens, or a positive history requiring medication within the last two months. Personal details of the two groups are shown in table 1 . Table 2 shows predicted values and measurements at entry to the study and four weeks after ketotifen and after 
